Effect of Capecitabine on the Pharmacokinetics of BMS-247550 and BMS-247550 on the Pharmacokinetics of Capecitabine and Its Metabolites in Patients With Advanced Malignancies

Completed · Phase 1

Conditions studied: Advanced Solid Tumors, Neoplasms

In brief

The purpose of this study is to test how BMS-247550 (ixabepilone) affects the removal of capecitabine from the body and how capecitabine affects the removal of BMS-247550 from the body.

Key facts

Study ID

NCT00207129

Run by

R-Pharm

People needed

25

Starts

2004-10-01

Expected to finish

2005-12-01

Last updated by the study team

2017-01-30

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Recovery from surgery or radiation therapy
• Measurable or non-measurable disease
• Available for follow-up

You may not qualify if…

• Neuropathy
• Uncontrolled pulmonary or cardiovascular disease
• Known history of HIV infection

Where it is running

• Local Institution — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.